Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.
- Home |
- Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
- March 26, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
